English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2528931      線上人數 : 187
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/6642


    題名: 改善TSB-9口服生體可用率之劑型研究
    Formulation Study for Improvement of Oral Bioavailability of TSB-9
    作者: 周政功
    Cheng-Kung Chou
    貢獻者: 藥學研究所
    關鍵詞: 固體分散相
    藥物動力學
    solid dispersion
    pharmacokinetics
    日期: 2006
    上傳時間: 2009-09-11 17:02:04 (UTC+8)
    摘要: 在本研究中我們所使用的模式藥物為TSB-9，是一種萃取自藤黃(Gamboge)中的混合物，其成分之一，Gambogic acid (GA)在許多的藥理研究中被認為對於癌細胞細胞週期中的G2期以及M期會產生不可逆的中止，所以有抑制腫瘤增生的功效。我們為了增加服藥時的方便性，所以本研究希望能以藤黃其中所有的成分製成複方TSB-9來口服投予給藥。
    根據我們的研究顯示出TSB-9口服吸收不好，口服生體可用率也極低，我們推測造成其口服吸收差可能的原因，應為低水溶解度、以及抑制胃腸道的蠕動導致藥物的吸收不佳，因此TSB-9口服藥物劑型的設計上，利用親水性的賦型劑PVP K-30、Kollidone VA-64、以及PEG6000將TSB-9製備成固體分散相增加其溶解度，以及給藥前先口服投予30 mg/kg的Metoclopramide預先增加胃腸道的活性，以避免TSB-9對胃腸道過度的抑制，期望TSB-9能被良好的吸收，進而增加其口服生體可用率。
    結果顯示TSB-9製備成固體分散相的劑型可以大幅的改善TSB-9溶解度，賦型劑所使用的比例越高則溶解度也越大。大白鼠口服以PVP K-30為賦型劑，比例為藥物比賦型劑為1:3，所製成之TSB-9固體分散相處方A13 投予劑量60 mg/kg時，於動物體內可以產生較大的曲線下面積以及最佳的生體可用率，其口服生體可用率是6.23%，約為同劑量的由0.5% tween 80所分散的TSB-9懸浮液2.27%之2.74倍。但是給藥前先口服投予 30 mg/kg的Metoclopramide並不能有效的增加藥物的口服生體可用率。
    所以將TSB-9製備成固體分散相之劑型可以有效改善其口服吸收差以及生體可用率低落的缺點，若將來製備成口服膠囊劑型可預期於癌症病患使用時，提高病患用藥的順服性。
    In this study, the model drug, TSB-9, is a poorly water-soluble mixture extracted from Garcinia hanburyi Hook. f.. Gambogic acid (GA) is one compound which was proved potent cytotoxicities against various cancer cell lines by irreversible arrest in G2/M phase of the cell cycle in Gamgoge. However, the oral bioavailability (BA) of TSB-9 is so low that we tried to increase it.
    We supposed the low oral BA of TSB-9 is because of its poor solubility and ability to inhibit the motility of gastrointestinal tract. Therefore, we formulated TSB-9 into solid dispersion (SD) by hydrophilic excipients, such as PVP K-30, Kollidone VA-64, and PEG6000 to increase its solubility. Beside, we gave a pre-dose of metoclopramide 30 mg/kg prior to TSB-9 administration to prevent the excessive GI tract inhibition.
    Base on the results of DSC, X-ray, and dissolution profile showed that TSB-9 formulated into SD could substantially increase its solubility. The more the proportion of excipients was added, the higher the solubility reached. Especially when the ratio of drug to PVP K-30 was 1:3, it obtained the highest area under curve (AUC) and the best oral BA about 6.23%, which is 2.74 times than that of TSB-9 suspension. But a pre-dose of metoclopramide 30 mg/kg prior to TSB-9 administration could not substantially increase its oral BA.
    In summary, formulating TSB-9 into SD could effectively improve its bad oral absorption and low BA. It would be beneficial to make TSB-9 into oral capsule to raise the compliance of cancer patients.
    資料類型: thesis
    顯示於類別:[藥學系] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    摘要.doc28KbMicrosoft Word85檢視/開啟
    摘要.pdf65KbAdobe PDF148檢視/開啟
    摘要.ppt97KbMicrosoft Powerpoint86檢視/開啟
    摘要.ps363KbPostscript54檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋